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Aims To study evolvement in pharmacotherapy of atrial ﬁbrillation from 1995 to 2004.
Methods and results All Danish patients were discharged following ﬁrst-time atrial ﬁbrillation and their
pharmacotherapy was identiﬁed by individual-level-linkage of nationwide registers of hospitalization
and drug dispensing from pharmacies. A total of 108 791 patients survived 30 days after discharge
and were included. In 1995–1996, 7.4% of the patients received beta-blockers, increasing to 44.3% in
2003–2004. The corresponding ﬁgures for amiodarone were 2.9 and 5.4%. In contrast, use of nondihydro-
pyridine calcium-channel blockers, digoxin, sotalol, and class 1C antiarrhythmics decreased from 20.6,
63.9, 21.3, and 4.0% in 1995–1996 to 12.6, 43.8, 4.2, and 1.3% in 2003–2004, respectively. Notably,
patients receiving anticoagulants increased from 29.8 to 43.5%. Multivariate logistic regression analysis
revealed females to be associated with more use of digoxin, but less use of amiodarone and oral antic-
oagulants than males. Patients above 80 years received less pharmacotherapy, apart from digoxin treat-
ment that was more commonly used in elderly.
Conclusion Pharmacotherapy of atrial ﬁbrillation has changed towards increased beta-blocker use with
a coincident decrease in the use of other rate-limiting drugs and sotalol. Treatment with amiodarone or
class 1C antiarrhythmics remained very low. Oral anticoagulant therapy increased considerably, but







For many clinicians treatment of atrial ﬁbrillation has
focused on restoration and maintenance of sinus rhythm
with direct-current cardioversion and administration of anti-
arrhythmic drugs. However, several recent trials have led to
this strategy being questioned.1–5 In the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
trial, there was an unexpected poor outcome in the rhythm-
control arm which could partly be explained by the adverse
effects of antiarrhythmic therapy and the less frequent
use of anticoagulation therapy.1 The extent to which
daily clinical practice in the treatment of atrial ﬁbrillation
has evolved during recent years remains unknown.
Therefore, we performed a nationwide study, using
individual-level-linkage hospital registries and prescriptions
dispensed from pharmacies to explore trends from 1995 to
2004 in the medical treatment of all 108 791 Danish patients
surviving ﬁrst-time admission for atrial ﬁbrillation.
Methods
Population
All permanent residents in Denmark have a unique civil registration
number that enables linkage between national registers on an indi-
vidual basis. Patients aged 30 years or older with ﬁrst hospitalization
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with atrial ﬁbrillation [International Classiﬁcation of Diseases 10th
revision (ICD-10) code I48] between 1995 and 2004 were identiﬁed
from the Danish National Patient Registry—a nationwide registry of
all hospitalizations in Denmark since 1978. Atrial ﬁbrillation as the
main condition, primary diagnosis, or as a coexisting condition, sec-
ondary diagnoses, was also identiﬁed. The database was systemati-
cally screened to ensure that any transfer of patients between
hospitals was registered as a single admission. Patients who died
within 30 days of discharge were excluded to ensure that all the
remaining patients had at least 30 days to obtain the prescribed
medicine from the pharmacy.
Medical treatment
The Danish Registry of Medicinal Product Statistics includes infor-
mation of all prescriptions dispensed from Danish pharmacies
since 1995. Each prescribed drug is coded according to the Anatom-
ical Therapeutical Chemical (ATC) classiﬁcation. The registry also
includes information about date of dispensing, strength and formu-
lation, quantity dispensed, and the afﬁliation of the doctor issuing
the prescription. This registry has been found to be accurate and
has been described in more detail previously.6,7 We identiﬁed all
prescriptions of beta-blockers (ATC code C07) including the most
frequently prescribed brands (atenolol ATC code CO7AB03, bisopro-
lol C07AB07, carvedilol ATC code CO7AG02, metoprolol ATC code
CO7AB02, and propanolol C07AA05), nondihydropyridine calcium-
channel blockers [verapamil and diltiazem (ATC code C08D)],
digoxin (ATC code C01A), sotalol (ATC code C07AA07), amiodarone
(ATC code C01BD01), Class 1C antiarrhythmics [propafenone (ATC
code C01BC03), and ﬂecainide (ATC code C01BC04)], and oral antic-
oagulant therapy [warfarin and phenprocoumon (ATC code B01AA03
and B01AA04)]. All ﬁrst prescriptions ﬁlled within 90 days from dis-
charge were included in our analyses.
Vital status
Information about each patient’s vital status (dead or alive) by the
end of December 2004 was obtained from the Central Population
Registry through Statistics Denmark, which records all cases of
death within 2 weeks.
Co-morbidity
To identify a possible inﬂuence of co-morbidity on choice of treat-
ment, we identiﬁed all patients with a present or previous
(5 years before index admission) diagnosis of: myocardial infarction
(ICD-10 code I21–22 and ICD-8 code 410), congestive heart failure
(ICD-10 code I50 and ICD-8 code 427.0 and 427.1), or ischaemic
stroke (ICD-10 code I63–66, I69.3, I69.4 and G65 and ICD-8 code
432–438). These diagnoses have been validated and have high posi-
tive predictive values.8–10 Furthermore, we identiﬁed the patients
admitted with atrial ﬁbrillation exclusively and without a previous
diagnosis of the aforementioned co-morbidities. These patients
were classiﬁed as ‘atrial ﬁbrillation without the pre-speciﬁed
co-morbidities’.
Statistical analysis
Multiple logistic regression was used to identify covariates associ-
ated with prescription of each of the aforementioned drugs. The
models were adjusted for calendar year (1995–1996 as reference),
age (30–59 years as reference), gender (women as reference), and
co-morbidity (no co-morbidity as reference). The age-related pre-
scription pattern was determined by dividing the patients into
four age groups: 30–59, 60–69, 70–79, and 80 years of age.
A level of 5% was considered statistically signiﬁcant including when
testing for interactions. All statistical calculations were performed
using the SAS statistical software package, version 9.1 for UNIX
servers (SAS Institute Inc., Cary, NC, USA).
Ethics
The Danish Data Protection Agency approved the study. Retrospec-
tive register-based studies do not require ethical approval in
Denmark.
Results
From 1995 to 2004, a total of 120 964 patients were hospi-
talized with a ﬁrst-time diagnosis of atrial ﬁbrillation in
Denmark. A total of 108 791 (89.9%) were alive 30 days
after discharge and were included in the analysis. The
mean age was 73.0 (+12.1) years and, on average,
women were signiﬁcantly older than men (Table 1).
Prescription pattern over time
Antiarrhythmic and rate-limiting drugs
During the 10-year study period, the proportion of atrial
ﬁbrillation patients treated with beta-blockers increased
from 7.4 to 44.3% (Figure 1). Of all beta-blockers (n ¼
25.479) metoprolol was most frequently used, accounting
for 19 488 (76.5%), atenolol 1701 (6.7%), bisoprolol 1534
(6.0%), carvedilol 1290 (5.1%), propanolol 860 (3.4%), and
other beta-blockers 606 (2.4%). In contrast, a considerable
decrease occurred in the use of digoxin, nondihydropyridine
calcium-channel blockers, and sotalol. The use of class 1C
antiarrhythmics and amiodarone remained low throughout
the study period, although there was an increase in the
use of amiodarone, from 2.9 to 5.4%, and a decrease in
Table 1 Baseline characteristics of the study sample
Characteristic n %
Total patients (mean age +SD,
years)
108 791 (73.0+12.1) 100.0
Women (mean age +SD,
years)
50 890 (76.5+10.8) 46.8







Year of atrial ﬁbrillation
1995–1996 19 003 17.5
1997–1998 19 997 18.4
1999–2000 22 483 20.7
2001–2002 24 478 22.5
2003–2004 22 830 21.0
Age (years)
30–59 15 531 14.3
60–69 20 908 19.2
70–79 36 420 33.5
80 35 932 33.0
Co-morbidity
Prior or concurrent myocardial
infarction
9896 14.0
Prior or concurrent congestive
heart failure
23 950 23.9






SD indicates standard deviation.
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the use of class 1C antiarrhythmics, from 4.0 to 1.3%.
Female gender was associated with signiﬁcantly more fre-
quent use of beta-blockers, nondihydropyridine calcium-
channel blockers, and digoxin than by males [the gender
difference increased with increasing age (age and gender
interaction, p , 0.001)], and less frequent use of amiodar-
one (Table 2). Increasing age was positively associated
with increased digoxin treatment, but negatively associated
with the use of any other antiarrhythmic drug treatment
(Table 2). A total of 9896 (9.1%) and 23 950 (22.0%) patients
were identiﬁed with a current or prior admission for myocar-
dial infarction or congestive heart failure. Treatment in
atrial ﬁbrillation patients with and without the speciﬁed
co-morbidities is illustrated in Figure 2. Similar trends in
treatment over time were observed for all subgroups, but
treatments with beta-blockers or digoxin were consistently
most common among myocardial infarction and congestive
heart failure patients (Table 2). Likewise, amiodarone was
most frequently prescribed to patients with a diagnosis of
myocardial infarction or congestive heart failure (Table 2).
Finally, treatment with nondihydropyridine calcium-channel
blockers, sotalol, and class 1C antiarrhythmics were most
common among atrial ﬁbrillation patients without the
speciﬁed co-morbidities (Table 2). The incidence of the
speciﬁed co-morbidities was stable throughout the period
of observation. Thus, the changes in prescription pattern
were not related to baseline co-morbidities as illustrated
in Figure 2.
Oral anticoagulants
The proportion of patients receiving oral anticoagulants
increased from 29.8 in 1995–1996 to 43.5% in 2003–2004
(Figure 1). The greatest increase was among patients older
than 80 years of age (age and calendar year interaction,
P, 0.001), but nevertheless they remained less likely to
receive treatment than those in younger age groups
(Figure 3A and Table 3). Female gender was associated
with signiﬁcantly less frequent use of anticoagulants than
by males, although the gender difference declined with
increasing age (age and gender interaction, P , 0.001;
Figures 3B and 4 and Table 3). Treatment with anticoagu-
lants was most common among patients with current or
prior ischaemic stroke (n ¼ 13 034, 12.0%) (Figure 3C and
Table 3).
Figure 1 Proportion of atrial ﬁbrillation patients who claimed a prescription of beta-blockers, nondihydropyridine calcium channel blockers,
digoxin, sotalol, amiodarone, class 1C-antiarrhythmics, or oral anticoagulants within 90 days of discharge.
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Table 2 Multivariate logistic regression analysis of factors associated with use of beta-blockers, nondihydropyridine calcium-channel blockers, digoxin, amiodarone, sotalol, and class 1C
antiarrhythmics in atrial ﬁbrillation patients
Variable % Beta-blockers Nondihydropyridine
calcium-channel
blockers
Digoxin Amiodarone Sotalol Class 1C
antiarrhythmics
OR % OR % OR % OR % OR % OR
Gender
Women 23.2 1.00 18.7 1.00 57.1 1.00 3.1 1.00 13.1 1.00 2.3 1.00
Men 23.6 0.89 (0.87–0.92) 16.2 0.83 (0.81–0.86) 49.4 0.85 (0.83–0.87) 5.5 1.45 (1.36–1.54) 16.5 0.97 (0.94–1.01) 3.0 0.96 (0.88–1.03)
Age
30–59 26.5 1.00 14.9 1.00 34.0 1.00 5.7 1.00 25.8 1.00 5.5 1.00
60–69 27.5 1.03 (0.98–1.09) 18.5 1.30 (1.23–1.38) 47.7 1.65 (1.58–1.73) 6.5 1.08 (0.98–1.18) 22.1 0.89 (0.85–0.94) 4.2 0.83 (0.76–0.92)
70–79 23.8 0.85 (0.81–0.89) 19.5 1.37 (1.30–1.44) 56.1 2.18 (2.09–2.27) 4.9 0.81 (0.74–0.88) 14.9 0.55 (0.53–0.59) 2.4 0.59 (0.45–0.55)
80 19.3 0.59 (0.56–0.62) 15.7 1.04 (0.99–1.10) 61.0 2.54 (2.43–2.65) 2.1 0.33 (0.30–0.36) 5.9 0.21 (0.20–0.23) 0.7 0.16 (0.12–0.17)
Co-morbidity
Myocardial infarction 38.1 2.38 (2.27–2.50) 13.3 0.72 (0.68–0.77) 48.4 0.67 (0.65–0.71) 9.4 2.17 (2.01–2.35) 14.5 1.27 (1.19–1.35) 1.3 0.59 (0.49–0.71)
Congestive heart failure 24.2 1.13 (1.09–1.18) 17.2 1.01 (0.97–1.05) 68.4 2.03 (1.96–2.09) 6.7 1.89 (1.77–2.02) 8.2 0.57 (0.54–0.60) 1.1 0.52 (0.46–0.60)
Ischaemic stroke 20.6 0.82 (0.78–0.86) 14.5 0.80 (0.75–0.84) 54.2 0.92 (0.88–0.95) 2.8 0.62 (0.55–0.69) 8.5 0.67 (0.63–0.72) 1.3 0.67 (0.57–0.79)
Atrial ﬁbrillation without the
pre-speciﬁed co-morbidities
20.6 1.00 (0.96-1.04) 19.4 1.07 (1.03–1.12) 44.8 0.78 (0.75–0.80) 3.3 0.73 (0.67–0.80) 25.8 1.65 (1.58–1.72) 5.0 1.49 (1.37–1.63)
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Discussion
The present study addresses the temporal trends in prescrip-
tion pattern of seven drugs frequently used in patients fol-
lowing ﬁrst-time hospitalization for atrial ﬁbrillation. Our
main ﬁndings were: (1) from 1995 to 2004 there was a
six-fold increase in the use of beta-blockers at the
expense of digoxin, nondihydropyridine calcium-channel
blockers, and sotalol; (2) sotalol, once the second most com-
monly used drug for treating atrial ﬁbrillation (21.3% of
cases in 1995–1996), was used in only 4.2% of patients in
2003–2004; (3) treatment with amiodarone and class 1C
antiarrhythmics remained infrequent throughout the
period of observation; (4) there was a considerable increase
in the use of oral anticoagulants; and (5) there was a sys-
tematic gender and age difference, with elderly patients
most likely to receive digoxin, and with women more fre-
quently receiving digoxin, and less frequently amiodarone
and anticoagulation therapy than their male counterparts.
Prescription pattern over time
In 2001, the ﬁrst AHA/ACC/ESC guidelines for the treatment
of atrial ﬁbrillation were published, based on a comprehen-
sive review of the literature from 1980 to 2001.11 These
guidelines describe various therapeutic options for the
treatment of patients with atrial ﬁbrillation, but do not rec-
ommend any particular therapeutic strategy or drug choice.
Therefore it is difﬁcult to explain the substantial changes in
prescription pattern in the present series of 108 791 unse-
lected patients with a ﬁrst-time diagnosis of atrial ﬁbrilla-
tion. Notably, changes in prescription pattern took place
from the very start of the study period, many years before
the AFFIRM, the Rate Control vs. Electrical Cardioversion
for Persistent Atrial Fibrillation (RACE) and other large
trials questioned the use of antiarrhythmic drugs in atrial
ﬁbrillation patients.1–5
One explanation for the increase in the use of beta-
blockers could be a ‘carry-over effect’ from beta-blocker
Figure 2 Proportion of atrial ﬁbrillation patients initiating antiarrhythmic and rate-lowering therapy according to co-morbidity.
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studies in non-atrial ﬁbrillation patients. In the 1980s, the
use of beta-blockers as a means of secondary prevention fol-
lowing myocardial infarction was shown to improve survival
by 20–25% and to reduce the risk of reinfarction.12 Also,
during the 1990s, evidence of the beneﬁt of beta-blockade
in heart-failure patients accumulated.13–15 This may have
inﬂuenced clinicians treating atrial ﬁbrillation patients,
many of whom had ischaemic heart disease or heart
failure, although nondihydropyridine calcium-channel
blockers in many ways are considered interchangeable
with beta-blockers in the treatment of atrial ﬁbrillation.16
Furthermore, beta-blocker treatment is not restricted to
speciﬁc types of atrial ﬁbrillation, as illustrated in The
Euro Heart Survey on Atrial Fibrillation, where the fre-
quency of beta-blocker use was 29–30% regardless of
whether the patients had ﬁrst-detected, paroxysmal, per-
sistent, or permanent atrial ﬁbrillation.17
In 1995–1996, almost two-thirds of all atrial ﬁbrillation
patients received treatment with digoxin, and although its
use declined considerably during the 10-year study period,
it continued to be frequently used. In agreement with
current guidelines, digoxin was most often prescribed to
congestive heart failure and elderly patients.16 Notably,
digoxin was more often used in female than in male
patients. This is a matter of concern, since female patients
may have a greater susceptibility to the adverse effects of
digoxin.18
Sotalol use decreased substantially during the study
period. This probably reﬂects the increased risk of death
and proarrhythmia associated with this drug19–22 and the
fact that sotalol is hardly more efﬁcient than conventional
beta-blockers for maintaining sinus rhythm.23
Throughout the 10-year observation period only a minority
of patients received amiodarone and class 1C antiarrhythmic
Figure 3 Proportion of atrial ﬁbrillation patients initiating treatment with oral anticoagulants from 1995 to 2004, by (A) age, (B) gender, and
(C) ischaemic stroke.
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drugs, even though these agents can maintain sinus
rhythm.24,25 The reluctance to use these agents outside
the hospital is understandable because of their potential
serious side effects.16 Furthermore, class 1C drugs are
restricted to patients without established ischaemic heart
disease or left ventricular dysfunction, which limits their
use in a population of atrial ﬁbrillation patients.16 The
minor decrease in amiodarone use from 2002 to 2004 could
be related to the publication of the ﬁndings of the AFFIRM
and RACE trials, which failed to show an advantage of
rhythm control of atrial ﬁbrillation over rate control.
Oral anticoagulants
The observed increase in atrial ﬁbrillation patients receiv-
ing anticoagulant therapy is in accordance with our pre-
vious report26 and reﬂects the impact of the large trials
that have proved the value of anticoagulation in high-risk
patients with atrial ﬁbrillation.27–32 Older age is a well-
known predictor of stroke among atrial ﬁbrillation
patients16,33 and we observed the greatest increase in
anticoagulant therapy among patients above 80 years of
age. However, elderly patients still remained less likely
to receive anticoagulation treatment than did those in
younger age groups, even in patients with a previous or
concomitant diagnosis of ischaemic stroke, for whom the
indication for anticoagulation treatment is particularly
strong. Increasing risk of haemorrhagic complications
associated with anticoagulant treatment in elderly
patients16,34 might restrain many physicians from prescrib-
ing this therapy, despite lower complication rates in newer
anticoagulation treatment regimes.16 We also demon-
strated that women less frequently received anticoagulant
therapy than did men throughout the observation period.
The gender-related difference in the anticoagulation
therapy was largest in the younger age groups, and might
reﬂect the fact that men acquire more risk factors for
stroke early in life than do their female counterparts.
Nevertheless, it is a matter of concern since females
with atrial ﬁbrillation have a higher risk of stroke than
their male counterparts.35–37
Limitations of the study
Due to the observational nature of this study there are
some limitations that need to be acknowledged. First,
although the diagnosis of atrial ﬁbrillation in the Danish
National Patient Registry has been validated,38 we did
not have any information on whether the individual cases
of atrial ﬁbrillation were paroxysmal, persistent, or perma-
nent. Secondly, the study is based on administrative regis-
tries that do not include clinical data. Thus, precise
indications for treatment of the individual patient are
not available. Thirdly, information about contraindication
for treatment and adverse reactions that might have led
to the treatment being withheld due to assessment of
the patient by the physician in charge is also not included
in the registries. Finally, although Denmark generally
follows the AHA/ACC/ESC guidelines for the treatment of
atrial ﬁbrillation, there may be individual differences
between countries in the pharmacotherapy and general
strategies of management of atrial ﬁbrillation.
Conclusion
Over the 10-year period there was a dramatic increase in
the use of beta-blockers in Danish atrial ﬁbrillation
patients at the expense of digoxin, nondihydropyridine
calcium-channel blockers, and sotalol. In fact, sotalol,
the second most used drug in 1995–1996, is rarely used
nowadays, while amiodarone and class 1C antiarrhythmics
still play a very modest role. Use of oral anticoagulants
has increased considerably, but there is a persistent under-
use of anticoagulation treatment in the elderly and in
women with atrial ﬁbrillation.
Conﬂict of interest: none declared.
Funding
This study was supported by research grants from the
Sanoﬁ-aventis Groupe and the Research Council of Eastern
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Table 3 Multivariate logistic regression analysis of factors






Men 42.4 1.40 (1.36–1.44)
Age
30-59 40.7 1.00
60-69 49.1 1.46 (1.40–1.52)
70-79 44.0 1.22 (1.17–1.27)
80 21.2 0.41 (0.39–0.43)
Co-morbidity
Myocardial infarction 36.6 0.70 (0.67–0.74)
Congestive heart failure 37.6 1.24 (1.20–1.28)
Ischaemic stroke 38.8 1.24 (1.19–1.29)
Atrial ﬁbrillation without the
pre-speciﬁed co-morbidities
32.3 0.97 (0.93–1.00)
Multiple logistic regression analysis adjusted for calendar year, age,
gender, and co-morbidity.
Figure 4 Proportion of women and men with atrial ﬁbrillation initi-
ating treatment with oral anticoagulants by age group.
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